{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:23:12Z","timestamp":1790338992032,"version":"4.1.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.pharmthera.2020.107586","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T07:48:33Z","timestamp":1590824913000},"page":"107586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Strategies for enhancing intratumoral spread of oncolytic adenoviruses"],"prefix":"10.1016","volume":"213","author":[{"given":"Nasser Hashemi","family":"Goradel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Negahdari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Ghorghanlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Jahangiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Arashkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.pharmthera.2020.107586_bb0005","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.gt.3302064","article-title":"Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy","volume":"10","author":"Ahmed","year":"2003","journal-title":"Gene Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0010","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/mt.2010.131","article-title":"Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model","volume":"18","author":"Ahmed","year":"2010","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/biomedicines2010036","article-title":"Oncolytic adenoviruses in cancer treatment","volume":"2","author":"Alemany","year":"2014","journal-title":"Biomedicines"},{"issue":"Pt 11","key":"10.1016\/j.pharmthera.2020.107586_bb0020","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"Journal of General Virology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0025","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0042-6822(90)90207-8","article-title":"Intracellular processing, glycosylation, and cell-surface expression of the measles virus fusion protein (F) encoded by a recombinant adenovirus","volume":"175","author":"Alkhatib","year":"1990","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107586_bb0030","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/jgm.616","article-title":"Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas","volume":"6","author":"Allen","year":"2004","journal-title":"The Journal of Gene Medicine"},{"issue":"25","key":"10.1016\/j.pharmthera.2020.107586_bb0035","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0040","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thoracic Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/cancers10060201","article-title":"Designer oncolytic adenovirus: Coming of age","volume":"10","author":"Baker","year":"2018","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107586_bb0050","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1242\/jcs.023887","article-title":"Tight junctions at a glance","volume":"121","author":"Balda","year":"2008","journal-title":"Journal of Cell Science"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107586_bb0055","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1128\/JVI.00118-11","article-title":"Unnatural amino acid incorporation onto adenoviral (Ad) coat proteins facilitates chemoselective modification and retargeting of Ad type 5 vectors","volume":"85","author":"Banerjee","year":"2011","journal-title":"Journal of Virology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0304-3835(98)00204-3","article-title":"The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy","volume":"131","author":"Baumgartner","year":"1998","journal-title":"Cancer Letters"},{"issue":"52","key":"10.1016\/j.pharmthera.2020.107586_bb0065","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1038\/sj.onc.1209040","article-title":"Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus","volume":"24","author":"Berk","year":"2005","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0070","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/jvi.67.10.5911-5921.1993","article-title":"Packaging capacity and stability of human adenovirus type 5 vectors","volume":"67","author":"Bett","year":"1993","journal-title":"Journal of Virology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0075","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.23647","article-title":"Overcoming physical barriers in cancer therapy","volume":"1","author":"Beyer","year":"2013","journal-title":"Tissue Barriers"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107586_bb0080","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/0008-5472.CAN-11-2009","article-title":"Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer","volume":"71","author":"Beyer","year":"2011","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0085","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ijc.28696","article-title":"Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans","volume":"135","author":"Bramante","year":"2014","journal-title":"International Journal of Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0090","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.mvr.2004.02.001","article-title":"Measurement of macromolecular diffusion coefficients in human tumors","volume":"67","author":"Brown","year":"2004","journal-title":"Microvascular Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107586_bb0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/microorganisms7080216","article-title":"New insights to adenovirus-directed innate immunity in respiratory epithelial cells","volume":"7","author":"Carlin","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0105","series-title":"Gene therapy protocols","first-page":"133","article-title":"PEGylated adenovirus for targeted gene therapy","author":"Catherine","year":"2008"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/mt.2010.209","article-title":"Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia","volume":"19","author":"Chen","year":"2011","journal-title":"Molecular Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107586_bb0115","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/sj.mt.6300264","article-title":"Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus","volume":"15","author":"Cheng","year":"2007","journal-title":"Molecular Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107586_bb0120","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2009.142","article-title":"Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy","volume":"17","author":"Choi","year":"2010","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Frontiers in Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107586_bb0130","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/gt.2013.10","article-title":"Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy","volume":"20","author":"Choi","year":"2013","journal-title":"Gene Therapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107586_bb0135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tim.2014.08.005","article-title":"Reovirus FAST proteins: virus-encoded cellular fusogens","volume":"22","author":"Ciechonska","year":"2014","journal-title":"Trends in Microbiology"},{"issue":"5392","key":"10.1016\/j.pharmthera.2020.107586_bb0140","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","article-title":"Reovirus therapy of tumors with activated Ras pathway","volume":"282","author":"Coffey","year":"1998","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107586_bb0145","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1128\/JVI.78.8.4342-4351.2004","article-title":"Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell-cell fusion","volume":"78","author":"Corcoran","year":"2004","journal-title":"Journal of Virology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0150","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.addr.2005.01.007","article-title":"CAR: A virus receptor within the tight junction","volume":"57","author":"Coyne","year":"2005","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0155","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1128\/jvi.70.3.1836-1844.1996","article-title":"Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues","volume":"70","author":"Crawford-Miksza","year":"1996","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0160","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1083\/jcb.136.3.729","article-title":"Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility","volume":"136","author":"Danielson","year":"1997","journal-title":"Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omto.2019.05.001","article-title":"An oncolytic adenovirus vector expressing p14 FAST protein induces widespread syncytium formation and reduces tumor growth rate in vivo","volume":"14","author":"Del Papa","year":"2019","journal-title":"Molecular Therapy Oncolytics"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2020.107586_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1040-8428(00)00086-X","article-title":"Multicellular resistance: a paradigm for clinical resistance?","volume":"36","author":"Desoize","year":"2000","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0175","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/JVI.02127-08","article-title":"Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters","volume":"83","author":"Dhar","year":"2009","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0180","series-title":"U. S. Food and Drug Administration. Imlygic (talimogene laherparepvec) prescribing information","author":"FDA, U. S","year":"2015"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107586_bb0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.virol.2005.06.030","article-title":"Synthesis, cellular localization, and quantification of penton-dodecahedron in serotype 3 adenovirus-infected cells","volume":"340","author":"Fender","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0190","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: Hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Advances in Virology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.gt.3301389","article-title":"Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies","volume":"8","author":"Fisher","year":"2001","journal-title":"Gene Therapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0200","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1525-0016(03)00092-3","article-title":"Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect","volume":"7","author":"Fu","year":"2003","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0210","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/clpt.2010.211","article-title":"Therapeutic potential of oncolytic measles virus: Promises and challenges","volume":"88","author":"Galanis","year":"2010","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107586_bb0215","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/104303401750148766","article-title":"Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas","volume":"12","author":"Galanis","year":"2001","journal-title":"Human Gene Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107586_bb0220","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/0008-5472.CAN-06-4260","article-title":"Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice","volume":"67","author":"Ganesh","year":"2007","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0225","first-page":"764","article-title":"Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts","volume":"62","author":"Geoerger","year":"2002","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107586_bb0230","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/ijc.23930","article-title":"Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs","volume":"123","author":"Goldoni","year":"2008","journal-title":"International Journal of Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107586_bb0235","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1128\/JVI.72.12.9479-9490.1998","article-title":"p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection","volume":"72","author":"Goodrum","year":"1998","journal-title":"Journal of Virology"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0240","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.taap.2017.09.022","article-title":"Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence","volume":"335","author":"Goradel","year":"2017","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0245","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1002\/jcp.27850","article-title":"Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches","volume":"234","author":"Goradel","year":"2019","journal-title":"Journal of Cellular Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107586_bb0250","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/jcp.27051","article-title":"Regulation of tumor angiogenesis by microRNAs: State of the art","volume":"234","author":"Goradel","year":"2019","journal-title":"Journal of Cellular Physiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0255","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/(SICI)1099-1654(1998100)8:4<213::AID-RMV225>3.0.CO;2-W","article-title":"Virus assembly and disassembly: The adenovirus cysteine protease as a trigger factor","volume":"8","author":"Greber","year":"1998","journal-title":"Reviews in Medical Virology"},{"issue":"23","key":"10.1016\/j.pharmthera.2020.107586_bb0260","first-page":"6891","article-title":"Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: Implications for antibody-based therapeutics of cancer","volume":"62","author":"Green","year":"2002","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107586_bb0265","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/gt.2011.184","article-title":"GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution","volume":"19","author":"Guedan","year":"2012","journal-title":"Gene Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107586_bb0270","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Molecular Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107586_bb0275","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/hum.2007.034","article-title":"Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors","volume":"18","author":"Hakkarainen","year":"2007","journal-title":"Human Gene Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107586_bb0280","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrm2927","article-title":"Adherens junctions: From molecules to morphogenesis","volume":"11","author":"Harris","year":"2010","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0285","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/jcp.26029","article-title":"Nanoparticles as new tools for inhibition of cancer angiogenesis","volume":"233","author":"Hashemi Goradel","year":"2018","journal-title":"Journal of Cellular Physiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0290","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1073\/pnas.1718957115","article-title":"Structures of the prefusion form of measles virus fusion protein in complex with inhibitors","volume":"115","author":"Hashiguchi","year":"2018","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0295","doi-asserted-by":"crossref","first-page":"a029157","DOI":"10.1101\/cshperspect.a029157","article-title":"Desmosomes and intermediate filaments: Their consequences for tissue mechanics","volume":"9","author":"Hatzfeld","year":"2017","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0300","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0305","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0310","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.cgt.7700071","article-title":"Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects","volume":"6","author":"Heise","year":"1999","journal-title":"Cancer Gene Therapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0315","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.cgt.7700071","article-title":"Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects","volume":"6","author":"Heise","year":"1999","journal-title":"Cancer Gene Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0320","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure - an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0325","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1146\/annurev.cellbio.12.1.627","article-title":"Virus-cell and cell-cell fusion","volume":"12","author":"Hernandez","year":"1996","journal-title":"Annual Review of Cell and Developmental Biology"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107586_bb0330","first-page":"6396","article-title":"Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: Implications for gene therapy","volume":"60","author":"Higuchi","year":"2000","journal-title":"Cancer Research"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107586_bb0335","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/sj.gt.3302806","article-title":"Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer","volume":"13","author":"Hoffmann","year":"2006","journal-title":"Gene Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107586_bb0340","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1158\/1535-7163.MCT-06-0790","article-title":"Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer","volume":"6","author":"Hoffmann","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0345","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.jid.5701131","article-title":"Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma","volume":"128","author":"Hoffmann","year":"2008","journal-title":"Journal of Investigative Dermatology"},{"issue":"22","key":"10.1016\/j.pharmthera.2020.107586_bb0350","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3748\/wjg.v13.i22.3063","article-title":"In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines","volume":"13","author":"Hoffmann","year":"2007","journal-title":"World Journal of Gastroenterology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0355","first-page":"673","article-title":"Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors","volume":"20","author":"Hoffmann","year":"2007","journal-title":"International Journal of Molecular Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0360","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4161\/cbt.6.4.3815","article-title":"Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy","volume":"6","author":"Hoffmann","year":"2007","journal-title":"Cancer Biology & Therapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107586_bb0365","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/1535-7163.MCT-06-0128","article-title":"Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy","volume":"5","author":"Hoffmann","year":"2006","journal-title":"Molecular Cancer Therapeutics"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107586_bb0370","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0375","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Letters"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007675","article-title":"Cell-cell fusion induced by reovirus FAST proteins enhances replication and pathogenicity of non-enveloped dsRNA viruses","volume":"15","author":"Kanai","year":"2019","journal-title":"PLoS Pathogens"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0385","first-page":"275","article-title":"Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells","volume":"8","author":"Kanerva","year":"2002","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0390","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40425-017-0276-8","article-title":"Durable response rate as an endpoint in cancer immunotherapy: Insights from oncolytic virus clinical trials","volume":"5","author":"Kaufman","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0395","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3","article-title":"Aberrant type I and type III collagen gene expression in human breast cancer in vivo","volume":"186","author":"Kauppila","year":"1998","journal-title":"The Journal of Pathology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0400","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.1996.135","article-title":"Identification and characterization of a widely expressed phosphate transporter\/retrovirus receptor family","volume":"49","author":"Kavanaugh","year":"1996","journal-title":"Kidney International"},{"issue":"20","key":"10.1016\/j.pharmthera.2020.107586_bb0405","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/jnci\/djj397","article-title":"Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy","volume":"98","author":"Kim","year":"2006","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0410","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0092-8674(00)81282-9","article-title":"The gap junction communication channel","volume":"84","author":"Kumar","year":"1996","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107586_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182715","article-title":"Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102\u2013support for clinical studies on advanced cancer treatment","volume":"12","author":"Kuryk","year":"2017","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107586_bb0420","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","article-title":"Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results","volume":"21","author":"Lang","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107586_bb0425","doi-asserted-by":"crossref","first-page":"19976","DOI":"10.18632\/oncotarget.5116","article-title":"Going viral: A review of replication-selective oncolytic adenoviruses","volume":"6","author":"Larson","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107586_bb0430","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3727\/096504013X13657689383139","article-title":"Therapeutic effect of oncolytic adenovirus expressing relaxin in radioresistant oral squamous cell carcinoma","volume":"20","author":"Lee","year":"2013","journal-title":"Oncology Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107586_bb0435","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/ijo.2015.3045","article-title":"The antitumor effects of oncolytic adenovirus H101 against lung cancer","volume":"47","author":"Lei","year":"2015","journal-title":"International Journal of Oncology"},{"issue":"18","key":"10.1016\/j.pharmthera.2020.107586_bb0440","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1089\/10430340152710504","article-title":"Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles","volume":"12","author":"Li","year":"2001","journal-title":"Human Gene Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107586_bb0445","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Current Cancer Drug Targets"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2020.107586_bb0450","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0455","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ymthe.2004.03.017","article-title":"An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency","volume":"9","author":"Liu","year":"2004","journal-title":"Molecular Therapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107586_bb0460","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1089\/hum.2017.033","article-title":"An oncolytic adenovirus encoding Decorin and granulocyte macrophage Colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune activation","volume":"28","author":"Liu","year":"2017","journal-title":"Human Gene Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003718","article-title":"Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells","volume":"9","author":"Lu","year":"2013","journal-title":"PLoS Pathogens"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0470","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/mt.2014.204","article-title":"Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy","volume":"23","author":"Martinez-Quintanilla","year":"2015","journal-title":"Molecular Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107586_bb0475","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1158\/1078-0432.CCR-15-1899","article-title":"The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma","volume":"22","author":"Martinez-Velez","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107586_bb0480","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/hum.2004.15.1022","article-title":"Biology of adenovirus and its use as a vector for gene therapy","volume":"15","author":"McConnell","year":"2004","journal-title":"Human Gene Therapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0485","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nbt942","article-title":"Antibody-targeted cell fusion","volume":"22","author":"Nakamura","year":"2004","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00086","article-title":"The role of the extracellular matrix in cancer stemness","volume":"7","author":"Nallanthighal","year":"2019","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107586_bb0495","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/v8120337","article-title":"Insights into adenovirus uncoating from interactions with integrins and mediators of host immunity","volume":"8","author":"Nemerow","year":"2016","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107586_bb0500","first-page":"2497","article-title":"Role of extracellular matrix assembly in interstitial transport in solid tumors","volume":"60","author":"Netti","year":"2000","journal-title":"Cancer Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0505","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"O\u2019Shea","year":"2004","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107586_bb0510","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/viro.2002.1510","article-title":"Adenovirus\u2013microbead conjugates possess enhanced infectivity: A new strategy for localized gene delivery","volume":"299","author":"Pandori","year":"2002","journal-title":"Virology"},{"issue":"51","key":"10.1016\/j.pharmthera.2020.107586_bb0515","doi-asserted-by":"crossref","first-page":"89391","DOI":"10.18632\/oncotarget.20810","article-title":"Hitting the nail on the head: Combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma","volume":"8","author":"Panek","year":"2017","journal-title":"Oncotarget"},{"issue":"476","key":"10.1016\/j.pharmthera.2020.107586_bb0520","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9321","article-title":"Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01","volume":"11","author":"Pascual-Pasto","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107586_bb0525","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1089\/hum.2005.16.1016","article-title":"Current status of gendicine in China: Recombinant human ad-p53 agent for treatment of cancers","volume":"16","author":"Peng","year":"2005","journal-title":"Human Gene Therapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107586_bb0530","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/13543784.2019.1694000","article-title":"DNX-2401: An investigational drug for the treatment of recurrent glioblastoma","volume":"28","author":"Philbrick","year":"2019","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0535","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/v8040112","article-title":"Measles virus fusion protein: Structure, function and inhibition","volume":"8","author":"Plattet","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0540","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-cellbio-101512-122422","article-title":"Virus and cell fusion mechanisms","volume":"30","author":"Podbilewicz","year":"2014","journal-title":"Annual Review of Cell and Developmental Biology"},{"issue":"32","key":"10.1016\/j.pharmthera.2020.107586_bb0545","doi-asserted-by":"crossref","first-page":"11715","DOI":"10.1073\/pnas.1408462111","article-title":"Structures and organization of adenovirus cement proteins provide insights into the role of capsid maturation in virus entry and infection","volume":"111","author":"Reddy","year":"2014","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0550","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1078-0432.CCR-14-2213","article-title":"Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression","volume":"21","author":"Rodriguez-Garcia","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0555","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1152\/physrev.1996.76.1.69","article-title":"Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction","volume":"76","author":"Ronnov-Jessen","year":"1996","journal-title":"Physiological Reviews"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107586_bb0560","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1128\/JVI.72.12.9470-9478.1998","article-title":"Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells","volume":"72","author":"Rothmann","year":"1998","journal-title":"Journal of Virology"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107586_bb0565","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.72.8.6875-6879.1998","article-title":"Circumvention of immunity to the adenovirus major coat protein hexon","volume":"72","author":"Roy","year":"1998","journal-title":"Journal of Virology"},{"issue":"7","key":"10.1016\/j.pharmthera.2020.107586_bb0570","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.003087-0","article-title":"Adenoviruses: Update on structure and function","volume":"90","author":"Russell","year":"2009","journal-title":"Journal of General Virology"},{"issue":"9","key":"10.1016\/j.pharmthera.2020.107586_bb0580","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.3390\/v6093563","article-title":"The adenovirus genome contributes to the structural stability of the virion","volume":"6","author":"Saha","year":"2014","journal-title":"Viruses"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107586_bb0585","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1128\/JVI.79.13.8090-8100.2005","article-title":"Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability","volume":"79","author":"Salsman","year":"2005","journal-title":"Journal of Virology"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0590","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/104303403321467199","article-title":"Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time points","volume":"14","author":"Sauthoff","year":"2003","journal-title":"Human Gene Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0595","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/104303403321467199","article-title":"Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time points","volume":"14","author":"Sauthoff","year":"2003","journal-title":"Human Gene Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0600","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41467-017-02707-6","article-title":"Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control","volume":"9","author":"Schmid","year":"2018","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0605","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.devcel.2003.08.001","article-title":"Polar expression of ErbB-2\/HER2 in epithelia. Bimodal regulation by Lin-7","volume":"5","author":"Shelly","year":"2003","journal-title":"Developmental Cell"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0610","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev-physiol-012110-142150","article-title":"Tight junction pore and leak pathways: A dynamic duo","volume":"73","author":"Shen","year":"2011","journal-title":"Annual Review of Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107586_bb0615","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1210\/er.2003-0013","article-title":"Relaxin\u2019s physiological roles and other diverse actions","volume":"25","author":"Sherwood","year":"2004","journal-title":"Endocrine Reviews"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0620","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/emboj\/19.5.902","article-title":"A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses","volume":"19","author":"Shmulevitz","year":"2000","journal-title":"The EMBO Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0625","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107586_bb0630","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1021\/nn8000565","article-title":"Nanoengineering artificial lipid envelopes around adenovirus by self-assembly","volume":"2","author":"Singh","year":"2008","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0635","first-page":"1","article-title":"Human adenovirus binding to host cell receptors: A structural view","author":"Stasiak","year":"2019","journal-title":"Medical Microbiology and Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0640","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/mt.2015.233","article-title":"Actin-resistant DNAse I expression from oncolytic adenovirus Enadenotucirev enhances its intratumoral spread and reduces tumor growth","volume":"24","author":"Tedcastle","year":"2016","journal-title":"Molecular Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107586_bb0645","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1128\/JVI.00082-09","article-title":"Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: Indirect complement activation by virions in vivo","volume":"83","author":"Tian","year":"2009","journal-title":"Journal of Virology"},{"issue":"6","key":"10.1016\/j.pharmthera.2020.107586_bb0650","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1034\/j.1600-0854.2003.00094.x","article-title":"Non-classical export of an adenovirus structural protein","volume":"4","author":"Trotman","year":"2003","journal-title":"Traffic"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107586_bb0655","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.3390\/v7122938","article-title":"Evidence for oncolytic virotherapy: Where have we got to and where are we going?","volume":"7","author":"Turnbull","year":"2015","journal-title":"Viruses"},{"issue":"24","key":"10.1016\/j.pharmthera.2020.107586_bb0660","doi-asserted-by":"crossref","first-page":"12109","DOI":"10.1128\/JVI.01370-06","article-title":"A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells","volume":"80","author":"Tuve","year":"2006","journal-title":"Journal of Virology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0665","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147211","article-title":"Characterization of the Antiglioma effect of the oncolytic adenovirus VCN-01","volume":"11","author":"Vera","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0670","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/bj2230587","article-title":"Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon","volume":"223","author":"Vogel","year":"1984","journal-title":"Biochemical Journal"},{"issue":"15","key":"10.1016\/j.pharmthera.2020.107586_bb0675","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"Journal of Virology"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0680","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103028","article-title":"Role of extracellular matrix in development and Cancer progression","volume":"19","author":"Walker","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"21","key":"10.1016\/j.pharmthera.2020.107586_bb0685","doi-asserted-by":"crossref","first-page":"10841","DOI":"10.1128\/JVI.01425-15","article-title":"Intracellular Signaling and Desmoglein 2 shedding triggered by human adenoviruses Ad3, Ad14, and Ad14P1","volume":"89","author":"Wang","year":"2015","journal-title":"Journal of Virology"},{"issue":"13","key":"10.1016\/j.pharmthera.2020.107586_bb0690","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1128\/JVI.00514-11","article-title":"Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions","volume":"85","author":"Wang","year":"2011","journal-title":"Journal of Virology"},{"issue":"1","key":"10.1016\/j.pharmthera.2020.107586_bb0695","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2020.107586_bb0700","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00018-007-7288-3","article-title":"Trypsin and trypsin-like proteases in the brain: Proteolysis and cellular functions","volume":"65","author":"Wang","year":"2008","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107586_bb0705","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/cgt.2016.41","article-title":"Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer","volume":"23","author":"Wong","year":"2016","journal-title":"Cancer Gene Therapy"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151516","article-title":"Adenovirus-mediated expression of the p14 fusion-associated small transmembrane protein promotes cancer cell fusion and apoptosis in vitro but does not provide therapeutic efficacy in a xenograft mouse model of cancer","volume":"11","author":"Wong","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107586_bb0715","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"Ai zheng= Aizheng= Chinese journal of cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2020.107586_bb0720","first-page":"1307","article-title":"Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer","volume":"22","author":"Xu","year":"2003","journal-title":"Ai zheng= Aizheng= Chinese Journal of Cancer"},{"issue":"44","key":"10.1016\/j.pharmthera.2020.107586_bb0725","doi-asserted-by":"crossref","first-page":"76666","DOI":"10.18632\/oncotarget.20800","article-title":"Adenovirus-mediated decorin expression induces cancer cell death through activation of p53 and mitochondrial apoptosis","volume":"8","author":"Yoon","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0730","first-page":"310","article-title":"Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer","volume":"22","author":"Yuan","year":"2003","journal-title":"Ai zheng= Aizheng= Chinese Journal of Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0735","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/hum.2016.022","article-title":"Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models","volume":"27","author":"Yumul","year":"2016","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2020.107586_bb0740","doi-asserted-by":"crossref","DOI":"10.1038\/npre.2008.1485.1","article-title":"Markedly enhanced intratumoral spread and antitumor effect of oncolytic adenovirus expressing decorin","author":"Yun","year":"2008","journal-title":"Nature Precedings"},{"issue":"3","key":"10.1016\/j.pharmthera.2020.107586_bb0745","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1073\/pnas.91.3.1168","article-title":"A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family","volume":"91","author":"van Zeijl","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0750","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.18632\/oncotarget.23869","article-title":"Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment","volume":"9","author":"Zhang","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.pharmthera.2020.107586_bb0755","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/1097-0142(19950215)75:4<1010::AID-CNCR2820750417>3.0.CO;2-O","article-title":"Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms","volume":"75","author":"Zhu","year":"1995","journal-title":"Cancer"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:06:55Z","timestamp":1759010815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820301145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":151,"alternative-id":["S0163725820301145"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107586","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for enhancing intratumoral spread of oncolytic adenoviruses","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107586"}}